ANG Lifesciences India Ltd.

BSE: 540694 SECTOR: Pharmaceuticals & Drugs  5164   44   1

582.60
-21.95 (-3.63%)
BSE: Today, 05:10 PM

Price Summary

Today's High

₹ 634.75

Today's Low

₹ 574.35

52 Week High

₹ 800.45

52 Week Low

₹ 0

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

603.96 Cr.

Enterprise Value

621.19 Cr.

No. of Shares

1.04 Cr.

P/E

85.94

P/B

15.2

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  38.33

CASH

3.6 Cr.

DEBT

20.83 Cr.

Promoter Holding

71.07 %

EPS (TTM)

₹  6.78

Sales Growth

4.22%

ROE

19.25 %

ROCE

22.39%

Profit Growth

7.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year4.22%
3 Year23.3%
5 Year28.05%

Profit Growth

1 Year7.91%
3 Year29.24%
5 Year72.08%

ROE%

1 Year19.25%
3 Year21.77%
5 Year30.67%

ROCE %

1 Year22.39%
3 Year22.76%
5 Year24.26%

Debt/Equity

0.6029

Price to Cash Flow

125.03

Interest Cover Ratio

3.4264774776902

CFO/PAT (5 Yr. Avg.)

0.979085374603084

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 71.07 21.11
Mar 2021 71.01 42.25
Sep 2020 71.01 67.54
Mar 2020 71.01 25.29
Sep 2019 71.01 25.29
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 23.2952994010977% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.767045188305% over the past 3 years.
  • Company has been maintaining healthy ROCE of 22.7594693159015% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 71.9102194897417 days.

 Limitations

  • The company is trading at a high EV/EBITDA of 43.0725.
  • Promoter pledging is high as 21.11%.

Quarterly Result (All Figures in Cr.)

Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 54.92 67.67 76.04 121.7 126.83
Total Expenditure 50.19 60.9 68.54 109.87 114.15
Operating Profit 4.73 6.77 7.5 11.83 12.68
Other Income 0.21 0.25 0.69 0.23 0.42
Interest 1.66 2.04 2.04 2.83 3.46
Depreciation 1.06 1.17 1.19 1.12 1.23
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.22 3.81 4.95 8.11 8.41
Tax 0.57 0.99 1.23 2.46 2.31
Net Profit 1.65 2.82 3.72 5.65 6.1
Adjusted EPS (Rs.) 2.25 3.83 3.59 5.45 5.88

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 3.68 3.68 5.18 5.18 5.18
Total Reserves 1.09 3.81 17.99 23.58 29.37
Borrowings 6.81 4.96 7.68 6.28 5.25
Other N/C liabilities 0.1 0.18 1.87 3.45 3.37
Current liabilities 23.81 34.21 35.45 42.4 50.9
Total Liabilities 35.49 46.84 68.17 80.9 94.08
Assets
Net Block 9.02 8.97 21.04 20.76 21.17
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.02 0.02 0.02 0.02 0.02
Loans & Advances 0 0.09 0.23 0.16 0.17
Other N/C Assets 0.05 0 0 0 0
Current Assets 26.39 37.76 46.87 59.96 72.71
Total Assets 35.49 46.84 68.17 80.9 94.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations 2.22 2.82 3.72 8.11 8.41
Adjustment 2.67 3.69 4 3.4 4.1
Changes in Assets & Liabilities -2.61 -1.13 -5.81 -1.68 -5.02
Tax Paid -0.42 -0.87 -1.03 -2.37 -2.65
Operating Cash Flow 1.86 4.51 0.88 7.46 4.83
Investing Cash Flow -2.92 -1.15 -13.4 -0.77 -1.66
Financing Cash Flow 1.63 -3.48 13.1 -3.8 -3.95
Net Cash Flow 0.56 -0.12 0.57 2.89 -0.77

Corporate Actions

Investors Details

PARTICULARS Sep 2019% Mar 2020% Sep 2020% Mar 2021% Sep 2021%
Promoters 71.01 71.01 71.01 71.01 71.07
rajesh gupta 70.81 70.81 70.81 70.81 70.81
saruchi gupta 0.19 0.19 0.19 0.19 0.19
PARTICULARS Sep 2019% Mar 2020% Sep 2020% Mar 2021% Sep 2021%
Investors 28.99 28.99 28.99 28.99 28.93
guiness securities... - 7.90 8.80 - -
ways vinimay priva... 6.91 - - 8.30 8.30
karvy stock brokin... - - 1.88 - -
globe capital mark... - - 1.54 1.70 -
display commercial... 1.48 - - - -
arun bhanot 1.33 - - - -
sanjay popatlal ja... - 1.20 - - -
jackpot vintrade p... - 1.08 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ2FY22 29 Oct 2021
  • PresentationQ1FY22 10 Sep 2021

ANG Lifesciences Stock Price Analysis and Quick Research Report. Is ANG Lifesciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into ANG Lifesciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 4.8307127 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. ANG Lifesciences has a Debt to Equity ratio of 0.6029 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In ANG Lifesciences , the EPS growth was 7.90666519856125 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, ANG Lifesciences has OPM of 9.99720619928296 % which is a bad sign for profitability.
     
  • ROE: ANG Lifesciences have a average ROE of 19.2525145809205 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about ANG Lifesciences

X